Asensus Surgical (ASXC) Stock Sees Sell-Off At Higher Level: A Good Buy Now?

The robotic surgery industry has grown at a fairly impressive clip over the...

Stay Ahead of the
Stock Market Game!
Subscribe to Small Cap
Exclusive for more

trending

See who picked Bellicum Pharmaceuticals (NASDAQ:BLCM)
Here's Who Just Picked Up Taiwan Fund Inc. (NYSE:TWN...
ICPT Stock Price is so consistent, can it go higher?...

The robotic surgery industry has grown at a fairly impressive clip over the course of the past few years and nowadays investors are becoming increasingly interested in this particular sector. One of the companies that could be of interest to such investors is Asensus Surgical (NYSEAMERICAN:ASXC), which is currently one of the notable players in the sector thanks to its main product Senhance System.

The product is meant for providing assistance during surgeries. However, if anyone is looking to analyze the Asensus stock then it is necessary to recognize that the situation may be a bit more complex. The most important thing to note that in addition to providing assistance for surgical procedures, Senhance System is also meant for cutting costs.

On the other hand, it is also necessary to remember that the Asensus stock had been caught up in the meme stock frenzy earlier this year and rallied hard as retail investors from Reddit piled on to the stock in a big way. As a matter of fact, the stock rallied by as much as 900% at the beginning of the year in a matter of few months.

However, such gains don’t last in general and it didn’t for the Asensus stock. The company’s product is ideal for laparoscopic surgeries since it is one type of surgery that has proven to be ideal for robotic solutions. Robotic surgery is expensive but Asensus has designed Senhance System in such a way that it can reduce costs by utilizing reusable standard instruments.

Stay in the lopp :

Celgene Switzerland Llc. Picked Juno Therapeu...
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Juno Therapeutics Inc. (NASDAQ:JUNO) reported that has picked up 10,350,833
P2 Capital Partners Picked Up Forrester Resea...
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Forrester Research Inc. (NASDAQ:FORR) reported that P2 Capital Partners has
Nascent Biotech NBIO Stock Price is ready for...

Nascent Biotech NBIO Stock Price his at a 52 week high, could it go even higher?

Wondering why this stock

related post

Skip to content